Industrial - Pollution & Treatment Controls
Compare Stocks
2 / 10Stock Comparison
ZONE vs NVAX
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
ZONE vs NVAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Industrial - Pollution & Treatment Controls | Biotechnology |
| Market Cap | $3M | $1.50B |
| Revenue (TTM) | $3M | $596M |
| Net Income (TTM) | $-123M | $-88M |
| Gross Margin | 58.5% | 84.6% |
| Operating Margin | -9.8% | -11.2% |
| Forward P/E | — | 3.6x |
| Total Debt | $5M | $249M |
| Cash & Equiv. | $1M | $241M |
ZONE vs NVAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 24 | May 26 | Return |
|---|---|---|---|
| CleanCore Solutions… (ZONE) | 100 | 11.6 | -88.4% |
| Novavax, Inc. (NVAX) | 100 | 213.2 | +113.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ZONE vs NVAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ZONE is the clearest fit if your priority is long-term compounding.
- -89.7% 10Y total return vs NVAX's -90.4%
NVAX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 2.11
- Rev growth 64.7%, EPS growth 306.5%, 3Y rev CAGR -11.1%
- Lower volatility, beta 2.11, current ratio 2.13x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 64.7% revenue growth vs ZONE's 29.2% | |
| Quality / Margins | -14.7% margin vs ZONE's -35.8% | |
| Stability / Safety | Beta 2.11 vs ZONE's 2.27 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +55.1% vs ZONE's -77.4% | |
| Efficiency (ROA) | -7.4% ROA vs ZONE's -121.3% |
ZONE vs NVAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
ZONE vs NVAX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
NVAX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVAX is the larger business by revenue, generating $596M annually — 174.2x ZONE's $3M. NVAX is the more profitable business, keeping -14.7% of every revenue dollar as net income compared to ZONE's -35.8%. On growth, ZONE holds the edge at +3.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $3M | $596M |
| EBITDAEarnings before interest/tax | -$33M | -$47M |
| Net IncomeAfter-tax profit | -$123M | -$88M |
| Free Cash FlowCash after capex | -$8M | -$96M |
| Gross MarginGross profit ÷ Revenue | +58.5% | +84.6% |
| Operating MarginEBIT ÷ Revenue | -9.8% | -11.2% |
| Net MarginNet income ÷ Revenue | -35.8% | -14.7% |
| FCF MarginFCF ÷ Revenue | -2.3% | -16.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.2% | -79.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.3% | -102.0% |
Valuation Metrics
Evenly matched — ZONE and NVAX each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $3M | $1.5B |
| Enterprise ValueMkt cap + debt − cash | $7M | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.46x | 3.63x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 2.56x |
| Price / SalesMarket cap ÷ Revenue | 1.48x | 1.34x |
| Price / BookPrice ÷ Book value/share | 2.10x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
NVAX leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NVAX scores 5/9 vs ZONE's 2/9, reflecting solid financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -130.7% | — |
| ROA (TTM)Return on assets | -121.3% | -7.4% |
| ROICReturn on invested capital | -93.9% | — |
| ROCEReturn on capital employed | -110.2% | +100.4% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 |
| Debt / EquityFinancial leverage | 3.69x | — |
| Net DebtTotal debt minus cash | $4M | $8M |
| Cash & Equiv.Liquid assets | $1M | $241M |
| Total DebtShort + long-term debt | $5M | $249M |
| Interest CoverageEBIT ÷ Interest expense | -37.28x | -5.10x |
Total Returns (Dividends Reinvested)
NVAX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ZONE five years ago would be worth $1,029 today (with dividends reinvested), compared to $524 for NVAX. Over the past 12 months, NVAX leads with a +55.1% total return vs ZONE's -77.4%. The 3-year compound annual growth rate (CAGR) favors NVAX at 7.4% vs ZONE's -53.1% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +14.3% | +29.5% |
| 1-Year ReturnPast 12 months | -77.4% | +55.1% |
| 3-Year ReturnCumulative with dividends | -89.7% | +23.9% |
| 5-Year ReturnCumulative with dividends | -89.7% | -94.8% |
| 10-Year ReturnCumulative with dividends | -89.7% | -90.4% |
| CAGR (3Y)Annualised 3-year return | -53.1% | +7.4% |
Risk & Volatility
NVAX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NVAX is the less volatile stock with a 2.11 beta — it tends to amplify market swings less than ZONE's 2.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVAX currently trades 77.1% from its 52-week high vs ZONE's 4.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.27x | 2.11x |
| 52-Week HighHighest price in past year | $7.82 | $11.97 |
| 52-Week LowLowest price in past year | $0.22 | $5.80 |
| % of 52W HighCurrent price vs 52-week peak | +4.6% | +77.1% |
| RSI (14)Momentum oscillator 0–100 | 56.0 | 64.4 |
| Avg Volume (50D)Average daily shares traded | 2.0M | 4.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $18.00 |
| # AnalystsCovering analysts | — | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.3% |
NVAX leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
ZONE vs NVAX: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ZONE or NVAX a better buy right now?
For growth investors, Novavax, Inc.
(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus 29. 2% for CleanCore Solutions, Inc. (ZONE). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Novavax, Inc. (NVAX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ZONE or NVAX?
Over the past 5 years, CleanCore Solutions, Inc.
(ZONE) delivered a total return of -89. 7%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: ZONE returned -89. 7% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ZONE or NVAX?
By beta (market sensitivity over 5 years), Novavax, Inc.
(NVAX) is the lower-risk stock at 2. 11β versus CleanCore Solutions, Inc. 's 2. 27β — meaning ZONE is approximately 8% more volatile than NVAX relative to the S&P 500.
04Which is growing faster — ZONE or NVAX?
By revenue growth (latest reported year), Novavax, Inc.
(NVAX) is pulling ahead at 64. 7% versus 29. 2% for CleanCore Solutions, Inc. (ZONE). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -172. 4% for CleanCore Solutions, Inc.. Over a 3-year CAGR, ZONE leads at -7. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ZONE or NVAX?
Novavax, Inc.
(NVAX) is the more profitable company, earning 39. 2% net margin versus -325. 3% for CleanCore Solutions, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -308. 1% for ZONE. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ZONE or NVAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ZONE or NVAX better for a retirement portfolio?
For long-horizon retirement investors, CleanCore Solutions, Inc.
(ZONE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZONE: -89. 7%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ZONE and NVAX?
These companies operate in different sectors (ZONE (Industrials) and NVAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.